A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

NCT00684593 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Navarixin 10 mg
OTHER: Placebo

Sponsor

Merck Sharp & Dohme LLC